Fig. 5From: Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatmentProposed “personalized” treatment algorithm for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis on the basis of the Granularity IndexBack to article page